<?xml version="1.0"?>

<document>
	<title>Antibiotic management of cystic fibrosis.</title>

	<author>Raeburn-J-A.</author>

	<source>J-Antimicrob-Chemother. 1976 Jun. 2(2). P 107-9.</source>

	<abstract>Cystic fibrosis is the most common autosomal recessive disorder in
   Great Britain, Central Europe and North America and it affects 1 in
   2000 live born children.  Does the antibiotic treatment in cystic
   fibrosis differ from the treatment of respiratory infection in other
   conditions?  The cystic fibrosis patient not only suffers progressive
   deterioration in respiratory function; he often has dangerous
   complicating conditions culminating in super-infection by highly
   resistant organisms.  The basic principle of antibiotic therapy must
   be rigidly applied in cystic fibrosis.  The first principle is to
   identify the pathogen and its susceptibility to antibiotics.  The
   second principle is to ensure that the chosen antibiotic reaches the
   site of infection.  The third principle is that the antibiotic
   therapy ought to complement the immunological defences of the
   patient.  A fourth principle is that no therapy must be given
   without first deciding upon the criteria which will be acceptable as
   indicating clinical improvement.</abstract>

	<majorsubject>ANTIBIOTICS: tu</majorsubject>
	<majorsubject>CYSTIC-FIBROSIS: co</majorsubject>
	<majorsubject>RESPIRATORY-TRACT-INFECTIONS:  dt</majorsubject>

	<minorsubject>RESPIRATORY-TRACT-INFECTIONS: co, mi</minorsubject>

	<reference>001   BEARN AG              CLIN GASTROENTEROL               2   515 973</reference>
	<reference>002   BRUMFITT W            J ANTIMICROB CHEMOTHER           1   163 975</reference>
	<reference>003   DIAZ F                J INFECT DIS                   121   269 970</reference>
	<reference>004   FORBES IJ             AUST NZ J MED                    2   160 971</reference>
	<reference>005   FORSGREN A            IN: BRENT L                          345 974</reference>
	<reference>006   LAWSON D              IN: WATT PJ                           69 970</reference>
	<reference>007   LEHRER RI             J CLIN INVEST                   50  2498 971</reference>
	<reference>008   MAY JR                CHEMOTHERAPY OF CHRONIC BRONC            972</reference>
	<reference>009   MAY JR                ARCH DIS CHILD                  47   908 972</reference>
	<reference>010   MCCRAE WM             IN: APLEY J                      4   157 974</reference>
	<reference>011   MCCRAE WM             SCOTT MED J                     19   187 974</reference>
	<reference>013   MEARNS MB             IN: MANGOS JA                        345 973</reference>
	<reference>014   RAEBURN JA            POSTGRAD MED J                  47   366 971</reference>
	<reference>015   RAEBURN JA            SCAND J INFECT DIS               5   135 973</reference>
	<reference>016   RAEBURN JA            IN: DAIKOS GK                    2   730 974</reference>
	<reference>017   SOLBERG CO            LANCET                           2   727 972</reference>

	<citation>1   RAEBURN JA            PROC NUTR SOC                   36    77 977</citation>
	<citation>2   GOVAN JRW             J ANTIMICROB CHEMOTHER           4   233 978</citation>
	<citation>3   GRAY JA               SCOTT MED J                     24   141 979</citation>
	<citation>4   MICHALSEN H           CHEMOTHERAPY                    26   135 980</citation>
	<citation>5   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    75 982</citation>
	<citation>6   HODSON ME             BR J DIS CHEST                  77    71 983</citation>

</document>
